REGN Regeneron Pharmaceuticals Inc
XNAS
813.27
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
REGN
$813.27
—
Key stats
$813.27
After hours
$820.52
+0.89%
- 52-Week Range
- $591.52 – $859.34
- YTD
- +4.76%
- IV Rank (30D)
- 76.93
- Straddle Price
- $68.25
- P/C Vol Ratio
- 8.83
- Market Cap
- $84.0B
- Open
- $807.06
- Day Range
- $802.20 – $821.16
- Volume
- 536,249
- Prev Close
- $816.10
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.00% |
| Beta vs SPY | 0.75 |
| Cost of Equity (CAPM) | 8.75% (VRP-adj) |
| WACC | 8.76% |
| Volatility Risk Premium | +10.1pp (IV − HV30) |
| Effective Tax Rate | 16.2% |
| Rev. Growth (YoY, DCF input) | +14.3% |
| DCF Horizon | 12 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $3.8B |
| Return on Equity (TTM) | 13.7% |
| Book / Price | 36.2% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 84.9% |
| FCF Margin (TTM) | 24.2% |
| Debt / Equity | 0.06 |
| Quality Score | 4/6 — high quality (12y DCF) |
| Market-Implied Growth | +7.8% (reverse-DCF on current price) |
| SMA 50 | $791.66 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $772.31 |
| Bollinger Width / SMA20 | 2.1% (drives anchor stability) |
| Net Debt | $-0.5B |
| Market Cap | $88B |
Peers used for multiples: ABT, NVS, PFE
(SIC-code peers; ETF co-membership was sector-incoherent)
60-Day Conviction
83%
20-Day Fair Value
≈ by Nov 26, 2026
$822.31
α +1.1%
rank 20%
conviction
65%
40-Day Fair Value
≈ by Dec 25, 2026
$838.96
α +3.2%
rank 22%
conviction
88%
60-Day Fair Value
≈ by Jan 25, 2027
$839.83
α +3.3%
rank 31%
conviction
83%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $1235.74 | 19% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $1745.07 | 6% | median 39.2× · 3 peers |
| Peer EV/EBITDA | $869.44 | 6% | median 19.4× · 3 peers |
| Peer P/B | $1048.43 | 6% | median 3.5× · 3 peers |
| Peer P/S | $620.66 | 6% | median 3.9× · 3 peers |
| Market Anchor (SMA50) | $791.66 | 38% | stability 100% (BB-width) |
| Options Expected (B-L 30d) | $817.68 | 19% | 46 strikes · skew +0.13 |
As of 2026-10-28 · updated
Related
About
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834) · industry map
- Exchange
- XNAS
- Market Cap
- $84.0B
- Employees
- 15,410
- List Date
- 1991-04-02
- CIK
- 0000872589
- Next Earnings
- 2026-10-30 (Pre-Market)
- EPS Forecast
- $16.36
- Headquarters
- Tarrytown, NY
- Homepage
- https://www.regeneron.com
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 4.34% | -2.95% | 5.27% | 4.17% | -5.90% | -4.49% | 0.07% |
| Feb | -11.32% | 0.82% | 0.32% | 0.87% | 4.78% | 3.53% | -0.17% |
| Mar | 2.18% | 15.06% | 6.65% | -2.07% | -7.39% | -2.30% | 2.02% |
| Apr | 1.34% | -5.14% | -2.95% | -8.11% | -2.96% | -9.03% | -4.47% |
| May | 2.83% | 1.95% | -8.82% | 8.49% | -16.90% | -12.35% | -4.13% |
| Jun | 10.99% | -10.29% | -1.73% | 6.22% | 6.97% | 3.81% | 2.66% |
| Jul | -0.00% | -2.30% | 3.32% | 2.10% | 1.97% | 21.83% | 4.49% |
| Aug | 16.68% | 0.76% | 11.83% | 8.37% | 3.91% | 5.25% | 7.80% |
| Sep | -11.13% | 14.69% | -1.04% | -10.06% | -2.70% | -7.96% | -3.03% |
| Oct | 12.11% | 1.85% | -4.66% | -19.94% | 8.64% | 10.68%* | 1.45% |
| Nov | -0.41% | -1.08% | 4.11% | -11.07% | 21.48% | -- | 2.61% |
| Dec | 0.15% | -5.22% | 7.78% | -6.56% | 2.90% | -- | -0.19% |
| Total | 26.79% | 5.30% | 19.81% | -27.86% | 10.28% | 4.45% | 6.46% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $775.06
SMA 50: $791.72
SMA 200: $736.37
Current: $813.27
EMA 12: $798.33
EMA 26: $787.39
MACD: 10.9430 | Signal: 5.5272
BULLISH
ADX (14): 22.81
WEAK TREND
+DI: 25.79
−DI: 13.50
Momentum Oscillators
RSI (14): 59.85
NEUTRAL
Stoch %K: 86.67
Stoch %D: 85.47
Williams %R: -13.22
Volume & Volatility
BB Upper: $839.04
BB Lower: $711.07
NEUTRAL
OBV: -7,930,686
Vol SMA 20: 644,831
Vol ROC: -39.25%
ATR: $20.49
True Range: $18.96
HV 20: 26.8%
HV 30: 27.6%
HV 60: 27.3%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-30T00:00:00 – 2026-10-28T00:00:00
AI Analysis
LLM Stock Analysis Report
Executive Summary
Overall assessment: BEARISH (confidence level: 7/10)
Key drivers and primary risks:
- Recent news headlines highlighting investor losses and securities fraud allegations
- Technical indicators pointing to overbought conditions and potential reversal
- Low volatility, indicating reduced market risk but also a lack of momentum
Investment thesis: Regeneron Pharmaceuticals' stock is likely to experience a pullback due to the cumulative negative news sentiment and technical warning signs. However, the low volatility environment suggests that this move may not be as extreme as previously seen.
Recent news sentiment impact: The recent news headlines have been overwhelmingly negative, with multiple reports of securities fraud allegations and investor losses. This has contributed to the bearish sentiment and potential reversal in the stock's price.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): NEUTRAL Medium-term (1-3 months): BEARISH Long-term (3-12 months): NEUTRAL
Support/Resistance Levels:
- Key resistance level: $845.52 (upper Bollinger Band)
- Key support level: $615.97 (lower Bollinger Band)
Momentum Signals: RSI interpretation: OVERBOUGHT (>70) - potential sell signal MACD signal: BULLISH, but the signal line is near the zero line, indicating a potential reversal Bollinger Bands position: NEUTRAL - price is near the middle band
Volume Analysis:
- Volume SMA 20: 781464.90 (low volume)
- On-Balance Volume (OBV): -19532445.33 (bearish signal)
- Volume Rate of Change: -83.71% (high volatility)
News & Sentiment Analysis
Recent Headlines Summary: Multiple reports of securities fraud allegations and investor losses have dominated the news.
Sentiment Assessment: NEGATIVE
Catalyst Identification: Upcoming earnings report may provide a catalyst for price movement.
Market Narrative: The recent negative news has driven the stock's price lower, while the technical indicators suggest a potential reversal.
Risk & Volatility Assessment
Beta Interpretation: Low beta (0.46) indicates that Regeneron Pharmaceuticals' stock moves less than the broader market.
Volatility Regime: Current volatility is low compared to historical levels.
Options Market Signals: IV rank: 1.2% (low), Current IV: 30.8%, Expected Move: $45.50 (28 DTE)
Downside Protection: Support level at $615.97 may provide a floor for the stock's price.
Market Context & Positioning
Sector Performance: Biotechnology sector has been relatively strong, but Regeneron Pharmaceuticals' stock has underperformed.
Institutional Activity: Low institutional interest and volume suggest that investors are not enthusiastic about the stock.
Correlation Analysis: The stock has a low correlation with the broader market (R-squared: 0.17), indicating that it may not be influenced by broader market trends.
Relative Valuation: The stock is trading near its lower Bollinger Band, suggesting that it may be relatively undervalued compared to historical levels.
Key Levels & Action Items
Critical Price Levels:
- Resistance level: $845.52 (upper Bollinger Band)
- Support level: $615.97 (lower Bollinger Band)
Breakout/Breakdown Levels: A breakout above the upper Bollinger Band or a breakdown below the lower Bollinger Band could trigger significant price movement.
Time-Sensitive Catalysts: Upcoming earnings report may provide a catalyst for price movement.
Risk Management: Investors should consider setting stop-loss levels at $615.97 and sizing their positions accordingly to manage risk.
Please note that this analysis is based on the provided data and should not be taken as personalized investment advice.
Generated
News
All REGN news →
Regeneron's biggest growth driver still has plenty of fuel left in the tank.
Boosted by its exclusive agreement with Regeneron, Kiniksa Pharmaceuticals stands among the top biotech stocks to watch. The post Biotech Stocks To Watch: Regeneron Partner Has Breakout In Sight appeared first on Investor's Business Daily .
Showing 1–10 of 22
Page 1 of 3
Earnings History
17 of 23 under expected move
Avg Expected Move
4.53%
Avg Actual Move
3.46%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-01-11 | Pre-Market | 4.13% | 0.84% | 0.20x | Within |
| 2021-05-06 | Pre-Market | 3.97% | 3.37% | 0.85x | Within |
| 2021-08-05 | Pre-Market | 4.08% | 3.70% | 0.91x | Within |
| 2021-11-04 | Pre-Market | 3.59% | 0.69% | 0.19x | Within |
| 2022-01-10 | Pre-Market | 4.78% | 2.91% | 0.61x | Within |
| 2022-05-04 | Pre-Market | 6.41% | 0.06% | 0.01x | Within |
| 2022-08-03 | Pre-Market | 6.23% | 5.88% | 0.94x | Within |
| 2022-11-03 | Pre-Market | 3.20% | 0.24% | 0.07x | Within |
| 2023-01-09 | Pre-Market | 3.83% | 7.69% | 2.01x | Exceeded |
| 2023-08-03 | Pre-Market | 4.37% | 5.37% | 1.23x | Exceeded |
| 2023-10-05 | Pre-Market | 1.81% | 1.98% | 1.09x | Exceeded |
| 2024-01-08 | Pre-Market | 3.44% | 1.13% | 0.33x | Within |
| 2024-05-02 | Pre-Market | 4.15% | 3.78% | 0.91x | Within |
| 2024-08-01 | Pre-Market | 4.83% | 1.29% | 0.27x | Within |
| 2024-10-31 | After-Close | 2.23% | 0.64% | 0.29x | Within |
| 2025-01-13 | After-Close | 4.74% | 3.63% | 0.77x | Within |
| 2025-04-29 | Pre-Market | 6.16% | 6.87% | 1.12x | Exceeded |
| 2025-08-01 | Pre-Market | 5.59% | 2.46% | 0.44x | Within |
| 2025-10-28 | Pre-Market | 5.42% | 11.82% | 2.18x | Exceeded |
| 2026-01-30 | Pre-Market | 5.68% | 1.07% | 0.19x | Within |
| 2026-04-29 | Pre-Market | 7.11% | 6.21% | 0.87x | Within |
| 2026-07-30 | Pre-Market | 6.14% | 6.17% | 1.00x | Exceeded |
| 2026-10-06 | Pre-Market | 2.36% | 1.69% | 0.72x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
REGN Options Activity & IV Rank
REGN IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 36.5%
7-DTE IV: 50.5%
Expected Move: $68.25
7-DTE Move: $48.45
Days to Exp: 30 (2026-11-27)
Options Flow
Call Volume: 24
Put Volume: 212
P/C Volume: 8.833
BEARISH
Call OI: 40
Put OI: 196
P/C OI: 4.9
Total OI: 236
ATM Options Pricing
ATM Call: $36.80
ATM Put: $31.45
Call %: 4.5%
Put %: 3.9%
Chain Summary
Chain Volume: 8,744
Chain OI: 36,734
Last Updated: 10/28/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
TYPICAL γ
Estimated net dealer gamma is at the 73rd percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
73%
vs own history
GEX tilt
+0.36
OI-weighted, today
Vanna tilt
+0.40
δ-sensitivity to IV
Charm tilt
-0.38
δ-decay vs time
Vanna tilt +0.40: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.38: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 168 ATM contracts, 11k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
51%
+8.1
pts
EXTREME
ATM 41.2% / Wing 49.4%
30 DTE / 10d
67%
+6.8
pts
EXTREME
ATM 36.6% / Wing 43.4%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)73.1MediumOct 28
IV Rank (30 DTE)76.9HighOct 28
Straddle Price (30 DTE)$68.25Oct 28
Beta Analysis
Risk Metrics
Beta: 0.4654
Alpha: 20.71%
Correlation: 0.1921
R-Squared: 3.7%
Stock Volatility: 30.8%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
REGN Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 107,375,000 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
35 filers$1.05B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $236.26M | 22.59% | 2026-06-30 |
| 2 | Jane Street Group, LLC Custodian | $198.66M | 18.99% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $169.17M | 16.17% | 2026-06-30 |
| 4 | IMC-Chicago, LLC Custodian | $109.43M | 10.46% | 2026-06-30 |
| 5 | Goldman Sachs Group Inc Custodian | $106.69M | 10.20% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $45.93M | 4.39% | 2025-09-30 |
| 7 | Bronte Capital Management Pty Ltd. | $42.77M | 4.09% | 2026-06-30 |
| 8 | Nantahala Capital Management, LLC | $24.94M | 2.38% | 2026-06-30 |
| 9 | Millennium Management LLC Custodian | $21.45M | 2.05% | 2026-06-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $13.78M | 1.32% | 2026-06-30 |
| 11 | Walleye Trading LLC | $11.22M | 1.07% | 2026-06-30 |
| 12 | SIG BROKERAGE, LP | $8.73M | 0.83% | 2026-06-30 |
| 13 | Simplex Trading, LLC Custodian | $8.42M | 0.80% | 2026-06-30 |
| 14 | TUDOR INVESTMENT CORP ET AL | $7.98M | 0.76% | 2026-06-30 |
| 15 | Cubist Systematic Strategies, LLC | $4.84M | 0.46% | 2025-09-30 |
| 16 | Allianz Asset Management GmbH | $4.61M | 0.44% | 2026-06-30 |
| 17 | Alphadyne Asset Management LP | $4.24M | 0.41% | 2026-06-30 |
| 18 | Squarepoint Ops LLC | $3.93M | 0.38% | 2026-06-30 |
| 19 | Qube Research & Technologies Ltd | $3.30M | 0.32% | 2026-06-30 |
| 20 | Balyasny Asset Management L.P. | $3.18M | 0.30% | 2026-06-30 |
| 21 | UBS Group AG Custodian | $2.87M | 0.27% | 2026-06-30 |
| 22 | PEAK6 LLC | $2.24M | 0.21% | 2026-06-30 |
| 23 | Verition Fund Management LLC | $1.93M | 0.18% | 2026-06-30 |
| 24 | BNP Paribas Financial Markets Custodian | $1.81M | 0.17% | 2026-06-30 |
| 25 | HSBC Holdings plc Custodian | $1.26M | 0.12% | 2026-06-30 |
33 filers$1.05B notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $432.67M | 41.05% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $164.99M | 15.65% | 2026-06-30 |
| 3 | Jane Street Group, LLC Custodian | $112.55M | 10.68% | 2026-06-30 |
| 4 | Marshall Wace, LLP Custodian | $79.19M | 7.51% | 2026-06-30 |
| 5 | IMC-Chicago, LLC Custodian | $71.52M | 6.79% | 2026-06-30 |
| 6 | Wolverine Trading, LLC Custodian | $36.50M | 3.46% | 2025-09-30 |
| 7 | LMR Partners LLP | $24.32M | 2.31% | 2026-06-30 |
| 8 | Millennium Management LLC Custodian | $22.51M | 2.14% | 2026-06-30 |
| 9 | Eisler Capital Management Ltd. | $16.08M | 1.53% | 2025-09-30 |
| 10 | GROUP ONE TRADING LLC Custodian | $13.28M | 1.26% | 2026-06-30 |
| 11 | Simplex Trading, LLC Custodian | $11.54M | 1.09% | 2026-06-30 |
| 12 | Walleye Trading LLC | $11.22M | 1.06% | 2026-06-30 |
| 13 | HSBC Holdings plc Custodian | $10.86M | 1.03% | 2026-06-30 |
| 14 | UBS Group AG Custodian | $7.86M | 0.75% | 2026-06-30 |
| 15 | Balyasny Asset Management L.P. | $5.61M | 0.53% | 2026-06-30 |
| 16 | Allianz Asset Management GmbH | $5.30M | 0.50% | 2026-06-30 |
| 17 | D. E. Shaw & Co., Inc. Custodian | $4.86M | 0.46% | 2026-06-30 |
| 18 | CAPSTONE INVESTMENT ADVISORS, LLC | $3.80M | 0.36% | 2026-06-30 |
| 19 | Verition Fund Management LLC | $3.80M | 0.36% | 2026-06-30 |
| 20 | Qube Research & Technologies Ltd | $2.62M | 0.25% | 2026-06-30 |
| 21 | Cubist Systematic Strategies, LLC | $2.47M | 0.23% | 2025-09-30 |
| 22 | BNP Paribas Financial Markets Custodian | $2.12M | 0.20% | 2026-06-30 |
| 23 | SHUFRO ROSE & CO LLC | $1.62M | 0.15% | 2026-06-30 |
| 24 | NOMURA HOLDINGS INC | $1.25M | 0.12% | 2026-06-30 |
| 25 | Alphadyne Asset Management LP | $1.25M | 0.12% | 2026-06-30 |
REGN Insider Trading (Form 4)
Latest: 2026-10-15Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-15 | Andrew J Murphy | Co-Chief Scientific Officer | Mixed | — | $570.46 | -$6.41M | EDGAR |
| 2026-09-03 | Kathryn Guarini | Director | Mixed | — | $784.68 | -$52.3K | EDGAR |
| 2026-09-03 | Marion McCourt | EVP Commercial | Sell (S) | −2,346 | $853.56 | -$2.00M | EDGAR |
| 2026-08-21 | Joseph J Larosa | EVP General Counsel and Secret | Mixed | +3,263 | $571.70 | -$2.80M | EDGAR |
| 2026-08-20 | Christopher R. Fenimore | EVP Finance CFO | Mixed | +1,684 | $564.30 | -$1.34M | EDGAR |
| 2026-08-12 | Huda Y Zoghbi | Director | Mixed | — | $588.35 | -$338.6K | EDGAR |
| 2026-08-12 | Kathryn Guarini | Director | Mixed | — | $759.68 | -$32.3K | EDGAR |
| 2026-07-07 | Arthur F Ryan | Director | Sell (S) | −200 | $650.15 | -$130.0K | EDGAR |
| 2026-05-04 | Arthur F Ryan | Director | Sell (S) | −100 | $705.24 | -$70.5K | EDGAR |
| 2026-04-03 | Arthur F Ryan | Director | Sell (S) | −100 | $777.27 | -$77.7K | EDGAR |
| 2026-03-03 | Arthur F Ryan | Director | Sell (S) | −100 | $785.50 | -$78.5K | EDGAR |
| 2026-02-23 | Huda Y Zoghbi | Director | Mixed | — | $579.01 | -$662.8K | EDGAR |
| 2026-02-11 | Arthur F Ryan | Director | Sell (S) | −100 | $778.53 | -$77.9K | EDGAR |
| 2026-02-11 | Jason Pitofsky | SVP Controller | Mixed | −1,036 | $684.14 | -$1.09M | EDGAR |
| 2026-01-08 | Bonnie L Bassler | Director | Mixed | — | $587.06 | -$638.8K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
REGN Insider Holdings
20 insiders · @ $813.27
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | George Yancopoulos | Bd. Co-Chair, President & CSO | 510,460 | $415.14M | -$467.64M | 57 | 2026-01-05 |
| 2 | Leonard S Schleifer | Bd. Co-Chair, President & CEO | 370,577 | $301.38M | -$458.80M | 50 | 2026-01-05 |
| 3 | Neil Stahl | EVP Research and Development | 53,434 | $43.46M | -$151.48M | 66 | 2024-12-18 |
| 4 | Andrew J Murphy | Co-Chief Scientific Officer | 52,760 | $42.91M | -$60.85M | 30 | 2026-10-15 |
| 5 | Joseph J Larosa | EVP General Counsel and Secret | 45,805 | $37.25M | -$42.93M | 46 | 2026-08-21 |
| 6 | Daniel P Van Plew | EVP & General Mgr, Industrial | 34,049 | $27.69M | -$135.29M | 55 | 2025-12-11 |
| 7 | George L Sing | Director | 31,407 | $25.54M | -$146.52M | 60 | 2026-01-06 |
| 8 | Christopher R. Fenimore | EVP Finance CFO | 24,608 | $20.01M | -$30.33M | 39 | 2026-08-20 |
| 9 | Arthur F Ryan | Director | 17,303 | $14.07M | -$59.42M | 81 | 2026-07-07 |
| 10 | Marion McCourt | EVP Commercial | 12,222 | $9.94M | -$32.98M | 61 | 2026-09-03 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
REGN Board & Officers
As of SEC filings through Oct 15, 2026Directors 13
- Arthur F Ryan · on file since 2006
- George L Sing · on file since 2006
- Joseph L Goldstein · on file since 2006
- Michael S Brown · on file since 2006
- George Yancopoulos · on file since 2006
- Leonard S Schleifer · on file since 2006
- Christine A Poon · since Nov 12, 2010
- Bonnie L Bassler · since Sep 9, 2016
- Huda Y Zoghbi · since Sep 9, 2016
- N Anthony Coles · since Jan 27, 2017
- Craig B. Thompson · since Oct 3, 2022
- David P Schenkein · since Sep 8, 2023
- Kathryn Guarini · since Sep 8, 2023
Officers 8
- Leonard S Schleifer · Bd. Co-Chair, President & CEO · listed since Dec 2023
- George Yancopoulos · Bd. Co-Chair, President & CSO · listed since Dec 2023
- Christopher R. Fenimore · EVP Finance CFO · listed since Dec 2025
- Joseph J Larosa · EVP General Counsel and Secret · listed since Dec 2019
- Andrew J Murphy · EVP Research · since Dec 11, 2019
- Marion McCourt · EVP Commercial · listed since May 2021
- Daniel P Van Plew · EVP & General Mgr, Industrial · listed since Aug 2021
- Jason Pitofsky · VP Controller · since Feb 6, 2024
Changes in the last 10 years (25)
| Dec 9, 2025 | Christopher R. Fenimore listed as EVP Finance CFO (previously SVP Finance & CFO) in SEC filings |
| Feb 12, 2024 | Christopher R. Fenimore listed as SVP Finance & CFO (previously SVP Controller) in SEC filings |
| Feb 6, 2024 | Jason Pitofsky became VP Controller |
| Dec 13, 2023 | Leonard S Schleifer listed as Bd. Co-Chair, President & CEO (previously President & CEO) in SEC filings |
| Dec 13, 2023 | George Yancopoulos listed as Bd. Co-Chair, President & CSO (previously President and Chief Scientific) in SEC filings |
| Sep 8, 2023 | The company announced the departure of Robert E Landry as EVP Finance CFO in an SEC filing |
| Sep 8, 2023 | Kathryn Guarini became a director |
| Sep 8, 2023 | David P Schenkein became a director |
| Sep 1, 2023 | The company announced the departure of Marc Tessier-Lavigne from the board in an SEC filing |
| Apr 14, 2023 | The company announced the departure of P Roy Vagelos from the board in an SEC filing |
| Apr 14, 2023 | The company announced the departure of P Roy Vagelos as Chairman of the Board in an SEC filing |
| Oct 3, 2022 | Craig B. Thompson became a director |
| Aug 24, 2021 | Christopher R. Fenimore listed as SVP Controller (previously VP Controller) in SEC filings |
| Aug 10, 2021 | Daniel P Van Plew listed as EVP & General Mgr, Industrial (previously EVP & General Mgr Industrial O) in SEC filings |
| May 10, 2021 | Marion McCourt listed as EVP Commercial (previously SVP Commercial) in SEC filings |
| May 29, 2020 | Sanofi reported in an SEC filing no longer being a 10% owner |
| Feb 25, 2020 | George Yancopoulos listed as President and Chief Scientific (previously President & CSO) in SEC filings |
| Dec 13, 2019 | Robert E Landry listed as EVP Finance CFO (previously SVP Finance & CFO) in SEC filings |
| Dec 13, 2019 | Joseph J Larosa listed as EVP General Counsel and Secret (previously SVP General Counsel and Secret) in SEC filings |
| Dec 11, 2019 | Andrew J Murphy became EVP Research |
| Feb 12, 2018 | Marion McCourt became SVP Commercial |
| Mar 2, 2017 | Christopher R. Fenimore became VP Controller |
| Feb 10, 2017 | George Yancopoulos listed as President & CSO (previously President Regeneron Laboratori) in SEC filings |
| Jan 27, 2017 | N Anthony Coles became a director |
| Dec 19, 2016 | Robert J Terifay listed as EVP Commercial (previously SVP Commercial) in SEC filings |
Not reported recently (5)
- Neil Stahl · Last reported as EVP Research and Development in an SEC filing dated Dec 18, 2024
- Charles A Baker · Last reported as a director in an SEC filing dated Jan 3, 2018
- Robert J Terifay · Last reported as EVP Commercial in an SEC filing dated Dec 13, 2017
- Michael S Aberman · Last reported as SVP Strategy Investor Relation in an SEC filing dated Jun 23, 2017
- Peter Powchik · Last reported as SVP Clinical Development & Reg in an SEC filing dated Dec 19, 2016
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
REGN Proposed Insider Sales (Form 144)
Latest: 2026-10-14
? Form 144 Guide
Last 30d:
1 filing
· $3.2M notice value
· Last 90d:
4 filings
· $5.1M notice value
· 4 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
MURPHY ANDREW J (1, $3.2M) · McCourt Marion (1, $969K) · Zoghbi Huda Y (1, $640K) · Guarini Kathryn (1, $320K)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-14 | MURPHY ANDREW J | Officer | 4,147 | $3.20M | 2026-10-14 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-09-03 | McCourt Marion | Officer | 1,131 | $969.3K | 2026-09-03 | UBS Financial Services Inc. | 10b5-1 | EDGAR |
| 2026-08-10 | Zoghbi Huda Y | Director | 800 | $640.0K | 2026-08-10 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-08-10 | Guarini Kathryn | Board member | 400 | $320.0K | 2026-08-10 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-07-02 | Arthur F. Ryan | Director | 400 | $249.9K | 2026-07-02 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-02-19 | Zoghbi Huda Y | Director | 1,638 | $1.29M | 2026-02-19 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-02-09 | Pitofsky Jason | Officer | 2,036 | $1.59M | 2026-02-09 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2026-02-09 | Arthur F. Ryan | Director | 400 | $314.2K | 2026-02-09 | J.P. Morgan Securities LLC | 10b5-1 | EDGAR |
| 2026-01-07 | Bassler Bonnie L | Director | 1,500 | $1.20M | 2026-01-07 | RBC CAPITAL MARKETS LLC | 10b5-1 | EDGAR |
| 2025-11-20 | Bassler Bonnie L | Director | 760 | $570.0K | 2025-11-20 | RBC CAPITAL MARKETS LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-04-29
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-29 | 0000872589-26-000014 | EDGAR |
| 2026-04-08 | 0001104659-26-040661 | EDGAR |
| 2026-01-30 | 0000872589-26-000004 | EDGAR |
| 2026-01-12 | 0001104659-26-002691 | EDGAR |
| 2025-10-28 | 0000872589-25-000026 | EDGAR |
| 2025-10-06 | 0001104659-25-096921 | EDGAR |
| 2025-08-01 | 0000872589-25-000017 | EDGAR |
| 2025-06-18 | 0001104659-25-060637 | EDGAR |
| 2025-04-29 | 0001804220-25-000020 | EDGAR |
| 2025-02-04 | 0001804220-25-000007 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-04 | 0000872589-26-000008 | EDGAR |
| 2025-02-05 | 0001804220-25-000011 | EDGAR |
| 2024-02-05 | 0001804220-24-000009 | EDGAR |
| 2023-02-06 | 0001804220-23-000008 | EDGAR |
| 2022-02-07 | 0001804220-22-000007 | EDGAR |
| 2021-02-08 | 0001804220-21-000008 | EDGAR |
| 2020-02-07 | 0001532176-20-000008 | EDGAR |
| 2019-02-07 | 0001532176-19-000009 | EDGAR |
| 2018-02-08 | 0001532176-18-000013 | EDGAR |
| 2017-02-09 | 0001532176-17-000008 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-29 | 0000872589-26-000016 | EDGAR |
| 2025-10-28 | 0000872589-25-000028 | EDGAR |
| 2025-08-01 | 0000872589-25-000019 | EDGAR |
| 2025-04-29 | 0001804220-25-000022 | EDGAR |
| 2024-10-31 | 0001804220-24-000040 | EDGAR |
| 2024-08-01 | 0001804220-24-000028 | EDGAR |
| 2024-05-02 | 0001804220-24-000017 | EDGAR |
| 2023-11-02 | 0001804220-23-000031 | EDGAR |
| 2023-08-03 | 0001804220-23-000023 | EDGAR |
| 2023-05-04 | 0001804220-23-000016 | EDGAR |
ETF Holders
394 ETFs hold REGN
25 shown · $14.37B total exposure · 0.23% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.10% | $2.4B | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.11% | $2.0B | — | 2026-09-30 |
| 3 | QQQ Invesco QQQ Trust, Series 1 | Invesco | 0.36% | $1.7B | — | 2026-10-26 |
| 4 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.12% | $1.1B | $885.1B | 2026-10-26 |
| 5 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.12% | $967.4M | $810.0B | 2026-10-26 |
| 6 | VO Vanguard Morningstar Mid-Cap ETF | Vanguard | 0.38% | $821.1M | — | 2026-09-30 |
| 7 | VTV Vanguard Morningstar Value ETF | Vanguard | 0.29% | $730.3M | — | 2026-09-30 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 5.67% | $615.0M | $11.0B | 2026-10-26 |
| 9 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 1.22% | $568.6M | $46.7B | 2026-10-26 |
| 10 | JEPI JPMorgan Equity Premium Income ETF | JPMorgan | 0.98% | $448.1M | $45.9B | 2026-10-27 |
| 11 | RDVY First Trust Rising Dividend Achievers ETF | First Trust | 1.65% | $419.1M | $25.4B | 2026-10-26 |
| 12 | QQQM Invesco NASDAQ 100 ETF | Invesco | 0.36% | $386.5M | — | 2026-10-26 |
| 13 | COWZ Pacer US Cash Cows 100 ETF | Nport | 1.36% | $254.3M | — | 2026-07-31 |
| 14 | VOE Vanguard Morningstar Mid-Cap Value ETF | Vanguard | 0.65% | $239.4M | — | 2026-09-30 |
| 15 | VHT Vanguard Health Care ETF | Vanguard | 1.09% | $238.7M | — | 2026-09-30 |
| 16 | JEPQ JPMorgan Nasdaq Equity Premium Income ETF | JPMorgan | 0.50% | $220.7M | $43.8B | 2026-10-27 |
| 17 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.12% | $219.7M | $183.4B | 2026-10-26 |
| 18 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.20% | $196.4M | — | 2026-10-26 |
| 19 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.21% | $175.7M | $83.0B | 2026-10-26 |
| 20 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.50% | $153.4M | $10.2B | 2026-10-26 |
| 21 | SCHG Schwab U.S. Large-Cap Growth ETF | Nport | 0.22% | $132.3M | — | 2026-05-31 |
| 22 | IVE iShares S&P 500 Value ETF | iShares (BlackRock) | 0.26% | $131.6M | $50.6B | 2026-10-26 |
| 23 | CGGO Capital Group Global Growth Equity ETF | Capitalgroup | 0.97% | $112.5M | $11.6B | 2026-10-26 |
| 24 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.53% | $105.9M | $3.0B | 2026-10-26 |
| 25 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.11% | $102.9M | $97.1B | 2026-10-26 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
20.10
TTM Diluted EPS
$40.47
TTM Revenue
$15.53B
TTM Net Income
$4.33B
TTM Op. Cash Flow
$4.68B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $4.29B | $1.30B | $12.23 | $813.00M |
| Q1 '26 | 2026-03-31 | $3.61B | $727.20M | $6.75 | $1.08B |
| Q4 '25 | 2025-12-31 | $3.88B | $844.60M | $7.87 | $1.17B |
| Q3 '25 | 2025-09-30 | $3.75B | $1.46B | $13.62 | $1.62B |
| Q2 '25 | 2025-06-30 | $3.68B | $1.39B | $12.81 | $1.14B |
| Q1 '25 | 2025-03-31 | $3.03B | $808.70M | $7.27 | $1.05B |
| Q4 '24 | 2024-12-31 | $3.79B | $917.70M | $8.11 | $1.26B |
| Q3 '24 | 2024-09-30 | $3.72B | $1.34B | $11.54 | $1.29B |
| Q2 '24 | 2024-06-30 | $3.55B | $1.43B | $12.41 | $354.00M |
| Q1 '24 | 2024-03-31 | $3.15B | $722.00M | $6.27 | $1.51B |
| Q4 '23 | 2023-12-31 | $3.43B | $1.16B | $10.20 | $1.09B |
| Q3 '23 | 2023-09-30 | $3.36B | $1.01B | $8.89 | $1.11B |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-30
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
20.10
P/B
2.75
P/S
5.62
EV/EBITDA
19.91
EV/Sales
5.59
ROE
13.7%
ROA
10.4%
Div Yield
0.45%
FCF Yield
5.36%
Debt/Equity
0.06
Current Ratio
—
Market Cap
$87.32B
as of 2026-10-28
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
2.15M
SI % of Float
2.25%
Days to Cover
2.49
Short Vol Ratio
40.1%
Free Float
95.71M
Float %
94.6%
Short interest 2026-09-30 • Short volume 2026-10-27 • Float 2026-08-24